StockData
enVVeno Medical Corp logo

enVVeno Medical Corp (NVNO) company profile

NVNONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 6/30
$5.77+0.00 (0.00%)

Close on Nov 18, 2026Market cap $4.01MP/E –Yield –

About enVVeno Medical

Surgical & Medical Instruments & Apparatus, SIC 3841

enVVeno Medical Corporation is a medical device company developing tissue-based bioprosthetic solutions to treat venous disease, specifically targeting patients with severe chronic venous insufficiency of the deep venous system. The company develops replacement venous valves to restore unidirectional blood flow toward the heart and lungs, counteracting blood pooling and high venous pressure in the lower legs. Its primary product pipeline centers on the enVVe System, a transcatheter, non-surgical replacement valve that includes a delivery device, accessories, nose cone, and crimping mechanism. The device aims to serve patients suffering from severe chronic venous insufficiency and related leg ulcers, with implant procedures intended for vascular surgeons, interventional radiologists, and interventional cardiologists.

The company conducts its development and manufacturing activities in a 14,507-square-foot leased facility located in Irvine, California. It has thirty-three full-time employees and holds intellectual property across global jurisdictions, including nine United States patents. enVVeno Medical Corporation maintains its corporate headquarters in Irvine, California.

Summary of the business section of enVVeno Medical's latest annual report, written by StockData.

Company profile

Company

Legal name
enVVeno Medical Corp
Founded
1999
Headquarters
Irvine, CA
Address
70 Doppler 92618
Phone
(949) 261-2900
Employees
12, Dec 31, 2019
Industry
Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Marcum LLP, New York, NY

Stock & identifiers

Ticker
NVNO
Former tickers
HJLI until Oct 1, 2021
Exchange
Nasdaq
IPO date
Jun 1, 2018
Shares outstanding
1M, Oct 27, 2026
Public float
$76.10M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-35 reverse, Jan 20, 2026; 1-for-25 reverse, Nov 30, 2020
SEC CIK
1661053
CUSIP
29415J205
ISIN
US29415J2050
FIGI
BBG000PVDC20
Share class FIGI
BBG001SRG4B9
LEI
549300KF5KREFECSNV87
EIN
33-0936180

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Robert Andrew BermanChief Executive Officer, Director22,236
Hamed AlaviChief Technology Officer8,334
Marc H. GlickmanSVP & Chief Medical Officer1,600
Jennifer BrightChief Financial Officer–
Francis DuhayDirector2,351
Matthew JenusaitisDirector16,545
Robert GrayDirector11,155
Sanjay ShrivastavaDirector9,288

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$583.76K-$166.04K$525.35K$6–
FY2024$1.16M$218.41K$483.56K$59–
FY2023$1.87M$2.15M$657.62K$101–
FY2022$466.48K-$1.02M$453.93K$77–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2024

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Robert A. Berman
Chief Executive Officer
$500.00K$232.50K$400.51K$28.12K$1.16M-38%
Craig Glynn
Chief Financial Officer
$250.00K$38.75K–$13.48K$302.23K-43%
Marc H. Glickman, M.D.
Chief Medical Officer and Senior Vice President
$367.50K$56.96K$150.19K$51.92K$626.57K-19%
Dr. Hamed Alavi
Senior Vice President & Chief Technology Officer
$300.00K$46.50K$150.19K$25.20K$521.90K-22%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 1, 2018
Offer price
$5.00
Securities offered
1,500,000
Gross proceeds
$7.50M
Exchange
Nasdaq
First trading day
May 31, 2018
First-day close
$5.24+4.8%
Lock-up ends (est.)
Nov 27, 2018

“Per Unit Total Public offering price $ 5.00 $ 7,500,000 Underwriting discounts and commissions(1) $ 0.45 $ 675,000 Proceeds to us, before expenses $ 4.55 $ 6,825,000 (1) See “Underwriting” beginning on page 115 of this prospectus for a description of the compensation payable to the underwriters.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?